KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER).

Yusuke Sano, Kana Miyazaki, Motoko Yamaguchi, Senzo Taguchi, Ryunosuke Machida, Kota Kawabata, Haruhiko Fukuda, Kazuyuki Shimada, Hirokazu Nagai, Wataru Munakata, Dai Maruyama, Japan Clinical Oncology Group Lymphoma Study Group

Jpn J Clin Oncol 56(3) 358-363

PMID41402979
PMCIDPMC13016924
DOI10.1093/jjco/hyaf202
发表日期2025-12-16
摘要

摘要

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Central nervous system (CNS) relapse is an uncommon yet lethal event in patients with DLBCL. Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisolone (pola-R-CHP) is a standard of care for patients with untreated DLBCL. In patients with DLBCL at high risk of CNS relapse, the intrathecal (IT) administration of methotrexate and cytarabine is widely adopted for CNS prophylaxis; however, the optimal treatment is unclear. The aim of this multicenter randomized phase III trial is to confirm the superiority of high-dose methotrexate administered during early cycles of pola-R-CHP in addition to IT chemotherapy for patients with untreated DLBCL at high risk of CNS relapse. A total of 390 patients from 52 institutions will be enrolled across a 4-year period. The primary endpoint is progression-free survival. This trial was registered in the Japan Registry of Clinical Trials as jRCTs031230505 [https://jrct.mhlw.go.jp/latest-detail/jRCTs031230505].

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。